Human Epidermal Growth Factor Receptor type 2 (HER2) overexpression cause more aggressive form of cancer, metastatic activity and chemo-resistance. Nanobodies (Nbs) are the smallest antibody-derived fragments with beneficial pharmacokinetic properties for molecular imaging and Targeted Radionuclide Therapy (TRT). Therefore, HER2-targeting nanobodies are very attractive vectors for TRT, especially when labeled with α-particle emitters, due to their small size (~15kDa), nM-range affinity, low immunogenicity, rapid clearance from blood and ease of tumor penetration. The goal of this study was to evaluate the therapeutic potential of the anti-HER2 Nb 2Rs15d labeled with 225Ac.
RODAK Magdalena;
DEKEMPENEER Yana;
WOJEWODZKA Maria;
LAHOUTTE Tony;
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
D’HUYVETTER Matthias;
PRUSZYNSKI Marek;
2022-03-28
ELSEVIER SCIENCE INC
JRC124540
0969-8051 (online),
https://www.sciencedirect.com/science/article/pii/S0969805121003176,
https://publications.jrc.ec.europa.eu/repository/handle/JRC124540,
10.1016/S0969-8051(21)00317-6 (online),
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Additional supporting files
| File name | Description | File type | |
|---|
